Cargando…

Tuberculosis in Patients with Primary Myelofibrosis During Ruxolitinib Therapy: Case Series and Literature Review

BACKGROUND: The selective Janus-activated kinase inhibitor ruxolitinib (rux) is now widely used to treat myelofibrosis and polycythemia vera due to its remarkable effect of reducing splenomegaly and improving constitutional symptoms. With opportunistic infections secondary to rux constantly reported...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Yizhou, Meng, Li, Hu, Xuemei, Han, Zhiqiang, Hong, Zhenya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532060/ https://www.ncbi.nlm.nih.gov/pubmed/33061478 http://dx.doi.org/10.2147/IDR.S267997

Ejemplares similares

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

Ruxolitinib therapy and telomere length in myelofibrosis
por: Caocci, G, et al.
Publicado: (2016)

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib
por: Abidi, Maheen Z., et al.
Publicado: (2016)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
por: Manduzio, Palma
Publicado: (2017)

Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
por: Rajasekaran, Arun, et al.
Publicado: (2015)

Evaluation of Ruxolitinib versus Best Available Therapy in Treating Primary Myelofibrosis
por: Hasan, Kawa M., et al.
Publicado: (2022)

Ruxolitinib therapy for myelofibrosis in Austria: Consensus on therapy management
por: Krauth, Maria-Theresa, et al.
Publicado: (2018)

Cryptococcal infection with ruxolitinib in primary myelofibrosis: A case report and literature review
por: Ciochetto, Zachary, et al.
Publicado: (2022)

Marked Hyperbilirubinemia Associated with Primary Myelofibrosis Responsive to Ruxolitinib
por: Sandhu, Sunny, et al.
Publicado: (2022)

PB2173: THE EFFECT OF RUXOLITINIB THERAPY ON HEMOSTATIC PARAMETERS IN PATIENTS WITH PRIMARY MYELOFIBROSIS
por: Korsakova, Natalia, et al.
Publicado: (2023)

Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2016)

Management of myelofibrosis after ruxolitinib failure
por: Harrison, Claire N, et al.
Publicado: (2020)

Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis
por: Hirano, Anna, et al.
Publicado: (2017)

Fatal Disseminated Tuberculosis during Treatment with Ruxolitinib Plus Prednisolone in a Patient with Primary Myelofibrosis: A Case Report and Review of the Literature
por: Tsukamoto, Yasuhiro, et al.
Publicado: (2017)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
por: Ostojic, Alen, et al.
Publicado: (2012)

Definition and management of ruxolitinib treatment failure in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2014)

Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis
por: Claudiani, Simone, et al.
Publicado: (2021)

Fatal Disseminated Tuberculosis and Concurrent Disseminated Cryptococcosis in a Ruxolitinib-treated Patient with Primary Myelofibrosis: A Case Report and Literature Review
por: Ogai, Asuka, et al.
Publicado: (2021)

Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib
por: Stoeva, Vera, et al.
Publicado: (2023)

Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
por: Li, Yujin, et al.
Publicado: (2020)

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
por: Verstovsek, Srdan, et al.
Publicado: (2023)

Posterior Reversible Encephalopathy Syndrome (PRES) in a Patient With Primary Myelofibrosis on Ruxolitinib
por: Shanthosh Kumar, Sandhya, et al.
Publicado: (2021)

Ruxolitinib Reduces Oxidative Stress in Patients With Primary Myelofibrosis: A Multicenter Study
por: Koyuncu, Mahmut B, et al.
Publicado: (2022)

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
por: Pacilli, Annalisa, et al.
Publicado: (2018)

Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications
por: Ross, David M., et al.
Publicado: (2021)

Real-life ruxolitinib experience in intermediate-risk myelofibrosis
por: Arikan, Fatma, et al.
Publicado: (2021)

Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report
por: Aylı, Meltem, et al.
Publicado: (2015)

P1058: REAL-WORLD OUTCOMES WITH FEDRATINIB THERAPY IN PATIENTS WITH PRIMARY MYELOFIBROSIS POST-RUXOLITINIB DISCONTINUATION
por: Passamonti, F., et al.
Publicado: (2022)

EBV reactivation mimicking a lymphoproliferative disorder associated with ruxolitinib therapy for myelofibrosis
por: Prem, Shruti, et al.
Publicado: (2019)

Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain
por: Gómez-Casares, María Teresa, et al.
Publicado: (2017)

Secondary Pulmonary Alveolar Proteinosis Associated with Primary Myelofibrosis and Ruxolitinib Treatment: An Autopsy Case
por: Sugiura, Hiroyuki, et al.
Publicado: (2020)

Ruxolitinib changes the natural course of myelofibrosis and its transplant outcome
por: Jung, Chul Won
Publicado: (2013)

Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2015)

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
por: Bryan, Jeffrey C., et al.
Publicado: (2016)

Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing
por: Mesa, Ruben A, et al.
Publicado: (2013)

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2019)

P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME
por: Palandri, F., et al.
Publicado: (2022)

P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
por: Xu, Z., et al.
Publicado: (2022)

Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis
por: Mikkelsen, Stine Ulrik, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dmllmes4jlutg43mji7go3b4du